• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

1.14 EUR+3.83 %31.7. klo 18.29
2,224 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.83 %
-40.93 %
-32.14 %
-51.07 %
-54.22 %
-66.07 %
-74.55 %
-
-77.47 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
42.62M EUR
Turnover
63.89K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Reduce
Target price
Updated
23.07.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Well then. At least the likes of the European Investment Bank and the Chairman of the Board believe in the company. I don’t think I’ll sell either, even though it’s been an annoyingly painful road.
22 hours ago
by JusaVaan
17
Aiforia’s conditional loan agreement provides a comfortable safety net. The EU wants to succeed in the competition between economic areas against the USA: “EIB Vice-President Karl Nehammer also highlighted the importance of European innovation in healthcare: ‘The solutions developed...
7 hours ago
by Vino Pino
12
There must be something right about this company for this kind of (albeit conditional) financing to go through. Now they need to show results in H2, and plenty of them. The upcoming interim report is a bit nerve-wracking, even with the good news currently circulating. I’m tempted...
18 hours ago
by Zamboni
8
Now that the financing is “secured,” it is time for the company to deliver on its promises. Contracts from large hospital districts alone will no longer suffice. We will be waiting to see the H2 development and clear communication on what these contracts actually mean. How is revenue...
10 hours ago
by Tulokas
7
Now that there is faith from the EU, how can public hospitals be encouraged to accelerate adoption? That is a tough nut for Aiforia to crack, and it won’t be easy. It is not enough for the product/service to be good; it also has to convince the users. Among them are some old-school...
4 hours ago
by Matti
5
If you can trust what’s being said, that funding came at the perfect time. “Our mission is to transform pathology image analysis with deep learning AI, and right now, the momentum is massive”
6 hours ago
4
The medium-term targets, which were confirmed to be in effect, indicate what this should actually mean. Regarding your cash flow concerns, the situation seems to be the opposite; that is, we have to record liabilities based on customer contracts when billing has occurred but the ...
9 hours ago
by Puutaheinää
4
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 23.07.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8.
2026

Interim report Q2'26

Regulatory press release31.07.2026 klo 18.00

Aiforia and the European Investment Bank have signed an agreement for EUR 20 million venture debt financing

Aiforia Technologies
Regulatory press release24.07.2026 klo 11.00

Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies
Third party research23.07.2026 klo 10.04

Aiforia Technologies: Aiforia H1 profit warning triggers downgrade to HOLD - NuWays AG Research

Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.75m, down from € 1.4m in H1'25 (-46% yoy), against our expectation of roughly doubling yoy, following last year's strong Clinical momentum (organic growth of +65%). At the same...

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Aiforia: We diagnose a growth deficiency
Research23.07.2026 klo 10.25 by
Antti Siltanen

Aiforia: We diagnose a growth deficiency

The ongoing uncertainty regarding growth is causing us to take a negative view of the risk-reward ratio.

Aiforia Technologies
Aiforia's H1 revenue was surprisingly subdued
Analyst Comment22.07.2026 klo 09.05 by
Antti Siltanen

Aiforia's H1 revenue was surprisingly subdued

The conversion of customer wins into revenue continues to be slow.

Aiforia Technologies
Regulatory press release21.07.2026 klo 18.40

Inside information, profit warning: Aiforia's revenue developed below the estimates during January–June 2026

Aiforia Technologies
Regulatory press release06.07.2026 klo 09.00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release06.07.2026 klo 09.00

Aiforia Technologies Plc – Managers’ Transactions – Johan Lundin

Aiforia Technologies
Regulatory press release01.07.2026 klo 21.00

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Acme Investments SPF Sarl)

Aiforia Technologies
Third party research29.06.2026 klo 10.21

Aiforia Technologies: € 6.4m share issue de-risks the investment case - NuWays AG Research

On Thursday evening, Aiforia announced having completed a directed share issue of 3.6m shares at € 1.772 per share, raising gross proceeds of some € 6.4m. The subscription price corresponds to the closing price of June 25th, representing no discount ...

Aiforia Technologies
Regulatory press release26.06.2026 klo 16.30

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release26.06.2026 klo 16.20

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Tuomas Tenkanen/TJT Technologies Oy)

Aiforia Technologies
Regulatory press release26.06.2026 klo 12.15

A total of 3,600,000 new shares in Aiforia Technologies Plc registered with the Trade Register

Aiforia Technologies
Aiforia collects 6.4 MEUR in a directed share issue
Analyst Comment26.06.2026 klo 08.49 by
Antti Siltanen

Aiforia collects 6.4 MEUR in a directed share issue

The company's financial risk in the coming years will diminish if the planned EIB loan materializes in addition to the share issue.

Aiforia Technologies
Regulatory press release25.06.2026 klo 22.00

Inside information: Aiforia Technologies Plc successfully completes a directed share issue raising approximately EUR 6.4 million

Aiforia Technologies
Regulatory press release25.06.2026 klo 18.31

Inside information: Aiforia Technologies Plc intends to carry out a directed share issue by means of an accelerated bookbuilding process

Aiforia Technologies
Third party research17.06.2026 klo 09.21

Aiforia Technologies: €20m EIB debt term sheet de-risks Aiforia's funding outlook - NuWays AG Research

Aiforia agrees non-binding EIB term sheet for up to €20m venture debt, materially de-risking the funding outlook. BUY, PT €3.80 unchanged.

Aiforia Technologies
Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB
Analyst Comment16.06.2026 klo 09.16 by
Antti Siltanen, Antti Luiro

Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB

The financing package would significantly reduce the short-term financing risk.

Aiforia Technologies
Regulatory press release15.06.2026 klo 21.45

Inside information: Aiforia and the European Investment Bank agree upon a non-binding indicative term sheet for an up to EUR 20 million venture debt financing facility

Aiforia Technologies
Aiforia expands to nine hospitals in Spain
Analyst Comment12.06.2026 klo 09.26 by
Antti Siltanen

Aiforia expands to nine hospitals in Spain

The news continues Aiforia's series of gradual growth steps with 9 new hospitals.

Aiforia Technologies